TENAX THERAPEUTICS, INC.
TENXDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TENX Earnings Report
EPS Est: $-0.38 | FQ end 2026-06
How TENX's past catalysts played out
TNX-103
Pulmonary Hypertension
Levosimendan
Hypertension Pulmonary Secondary
perfluorocarbon emulsion (Oxycyte) infusion
Traumatic Brain Injury
Levosimendan 2.5 mg/ml Injectable Solution
Hypertension Pulmonary Secondary Heart Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TNX-103 | Phase 3 | Pulmonary Hypertension | - | - |
Levosimendan | Phase 2 | Hypertension Pulmonary Secondary | - | - |
perfluorocarbon emulsion (Oxycyte) infusion | Phase 2 | Traumatic Brain Injury | - | - |
Levosimendan 2.5 mg/ml Injectable Solution | Phase 2 | Hypertension Pulmonary Secondary Heart Failure | - | - |
Hypertension Pulmonary Secondary
1 drug in this indication
Hypertension Pulmonary Secondary Heart Failure
1 drug in this indication
Pulmonary Hypertension
1 drug in this indication
Coronary Artery Bypass Grafting
1 drug in this indication
Traumatic Brain Injury
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TENAX THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in TENAX THERAPEUTICS, INC.'s (TENX) pipeline across Phase 3, Phase 2. Its lead program is TNX-103 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TENAX THERAPEUTICS, INC.'s next FDA catalyst?→
TENAX THERAPEUTICS, INC.'s (TENX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TENX biotech catalysts?→
Add TENX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TENAX THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.